Psoriasis | Bausch Health | BHS-CAN-DERM-002
Pharmaceutical Company/Sponsor:
Bausch Health
Code:
BHS-CAN-DERM-002
Title:
A Canadian Phase IV, Multicenter, Single-Arm Study To Evaluate the Effectiveness of Treatment With Brodalumab (SILIQ) in Psoriasis Patients With Inadequate Response to Their Current Biologic Agent Regimen
Type:
Observational
Phase:
4
Condition/Disease:
Psoriasis
Intervention(s)/Treatment(s):
Drug: Brodalumab
Status:
Recruiting
Link for Additional Information:
